|
Grade, n%
|
CPB (n = 124)
|
CPA (n = 122)
|
HR (95%)
|
p-value
|
|---|
|
≥ 2 genitourinary fistula
|
0 (0)
|
0 (0)
|
NA
|
1.000
|
|
≥ 2 gastrointestinal fistula
|
0 (0)
|
0 (0)
|
NA
|
1.000
|
|
≥ 3 gastrointestinal bleeding
|
0 (0)
|
0 (0)
|
NA
|
1.000
|
|
≥ 2 hypertension
|
31 (25.0)
|
5 (4.1)
|
7.00 (4.52–6.02)
|
< 0.001*
|
|
≥ 4 neutropenia
|
42 (33.9)
|
18 (14.8)
|
4.00 (3.83–5.36)
|
< 0.001*
|
|
≥ 3 thrombosis/embolism
|
11 (8.9)
|
3 (2.5)
|
2.00 (1.48–3.71)
|
0.030*
|
|
≥ 2 pain
|
38 (30.6)
|
34 (27.9)
|
3.00 (0.14–4.23)
|
0.633
|
- *Statistically significant. CPB cisplatin-paclitaxel chemotherapy plus bevacizumab, CPA cisplatin-paclitaxel chemotherapy alone, HR Hazard ratio, NA not applicable
